News

San Francisco – September 25, 2026 -- Omneky has launched TASTE BENCH, an evaluation suite that scores whether AI-generated image and video ads are ready to run without human rework.

GPT Image 2.5 Sunburst leads eight models with a 54.2% ready-to-run rate

In first-attempt tests across eight image models, GPT Image 2.5 Sunburst produced ready-to-run ads 54.2% of the time (32 of 59 briefs), scoring an average quality of 7.38 out of 10. Ready-to-run rates across all eight models ranged from 22.0% to 54.2%, with Omneky's own review step disabled during testing.

The benchmark covers 469 ads generated across four brands and five languages

The current edition of TASTE BENCH spans eight image models, 59 ad briefs, four brands, and five languages -- English, Japanese, Arabic, Hindi, and Spanish. The tests generated 469 ads and produced 1,371 valid blind judge reviews.

Waterloo, ON – September 25, 2026 -- OpenText Corporation (NASDAQ: OTEX; TSX: OTEX) has slashed the ceiling on its cash tender offer for outstanding 3.875% Senior Notes due 2028 to $300 million from $450 million, while pushing back key deadlines by one day.

OpenText lowers aggregate maximum tender amount by $150 million

The amended terms cut the Aggregate Maximum Tender Amount for the Bonds from $450 million to $300 million aggregate principal amount, according to the company's announcement modifying the Offer to Purchase dated September 23, 2026.

Tampa – September 25, 2026 -- Colony Grill has signed on as the Official Pizza Partner of the Tampa Bay Buccaneers, placing its thin-crust pizza in Raymond James Stadium through the 2030 season.

Four concession stands and premium suites will carry Colony Grill's menu

The deal covers three signature items -- plain cheese, pepperoni and the Original Hot Oil Pizza -- sold at four concession locations in Sections 109, 134, 311 and 336. Club-level seating will offer in-seat delivery in co-branded Colony Grill and Buccaneers personal-sized pizza boxes, while larger-format pizzas will be available in suites, the Champions Club and the Hall of Fame Club.

New York – September 25, 2026 -- European companies participating in the UN Global Compact posted an average sustainability contribution score of 58.2 out of 100, according to the second edition of the European Private Sector SDGs Stocktake released around the United Nations General Assembly.

The study, compiled by UN Global Compact Networks in Bulgaria, Finland, France, Germany, Italy, the United Kingdom and Türkiye, analyzed 136 data points from 5,793 participant companies across 21 European countries. It marks the first attempt to quantify the private sector's contribution to the 2030 Agenda at this scale.

Health commitments outperform environmental action across Europe

SDG 3 on health recorded the highest contribution score at 73.6, while climate action under SDG 13 lagged at 45.8. Only 28.1% of responding companies have developed a climate adaptation plan, exposing a gap between stated commitments and operational execution.

Shanghai – September 25, 2026 -- Nutshell Therapeutics (Shanghai) Co., Ltd. has received FDA clearance of its Investigational New Drug (IND) application for NTS231, a covalent allosteric molecular glue degrader targeting NRF2, allowing the company to begin clinical development in the United States. NTS231 is the first NRF2 degrader originating from China and only the second such molecule worldwide to reach clinical-stage development.

New York – September 25, 2026 -- A $900 million utility-tech agreement, a $140 million biotech raise and a machine-vision acquisition topped this week's most consequential B2B disclosures distributed via PR Newswire.

Georgia Power and Google strike $900 million nuclear capacity deal

Georgia Power and Google reached an agreement projected to deliver approximately $900 million in customer benefits while expanding nuclear generation in Georgia. Pending approval from the Georgia Public Service Commission, Google will support uprates at the utility's Plant Vogtle and Plant Hatch nuclear units, adding roughly 96 megawatts of new grid capacity.

Delray Beach, Fla. – September 25, 2026 -- The global aseptic packaging market will expand from USD 87.87 billion in 2026 to USD 123.76 billion by 2031, a 7.09% compound annual growth rate, according to MarketsandMarkets.

Vials, ampoules and prefillable syringes post the fastest growth at 8.48% CAGR

The pharmaceuticals application segment is set to register the market's highest growth rate as biological drugs, vaccines, monoclonal antibodies and biosimilars require sterile filling that standard terminal heat sterilization cannot achieve. Prefillable syringes and single-dose sterile containers are gaining clinical adoption to reduce medication errors and drug wastage, prompting pharmaceutical manufacturers to deploy mechanized aseptic filling lines under stricter regulatory oversight.

New York – September 25, 2026 -- Global healthcare, investment, philanthropy and government leaders convened at a roundtable on the sidelines of the 81st United Nations General Assembly to address a women's health gap that the World Economic Forum projects could exceed $1 trillion annually by 2040 if unaddressed. The session, titled "The $1 Trillion Case for Women's Health," was convened by Burjeel Holdings, a super-specialty healthcare provider operating across the UAE, Oman and Saudi Arabia.

Saudi Ambassador Reema Bandar Al-Saud calls for lifelong, integrated women's healthcare investment

HRH Ambassador Reema Bandar Al-Saud, Saudi Arabia's envoy to the United States, opened the roundtable with a virtual address urging governments to treat women's physical and mental health as interconnected rather than episodic. She argued that no nation can rely on half its population to drive economic growth while leaving their healthcare needs to chance.

Raritan, N.J. – September 25, 2026 -- Half of patients with early-line relapsed or refractory multiple myeloma treated with a single infusion of Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) remained alive and progression-free for at least five years without maintenance therapy, according to new long-term data from the Phase 2 CARTITUDE-2 study.

Half of patients reach five-year progression-free survival without maintenance

In the initial subgroup of cohort A (N=20), 10 of 20 patients treated with a single CARVYKTI® infusion remained progression-free at a median follow-up of 60.7 months. Median progression-free survival reached 60.5 months, and the results were presented at the International Myeloma Society Annual Meeting (Abstract #PA-288). Cohort A enrolled patients who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide.

Hong Kong – September 25, 2026 -- Eventus won Market Surveillance Solution of the Year for its Validus platform at the FOW Asia Pacific Awards in Hong Kong, marking one of 17 honors the firm has collected in the APAC region alone.

Validus platform secures back-to-back industry recognition across markets

The APAC win follows Eventus' fourth consecutive win in the same category at the FOW International Awards earlier this year. It also comes after the firm was named Best Trade Surveillance Solution in the July 2026 Capital Markets Technology Awards APAC and Trade Surveillance Product of the Year in the global Risk Technology Awards.